Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding study of norursodeoxycholic acid in primary sclerosing cholangitis
2011-002754-31Phase 2Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of norursodeoxycholic acid in Primary Sclerosing Cholangitis (PSC) (4 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Change in serum alkaline phosphatase. Started May 2012; status: completed.
02
Drugs
norursodeoxycholic acid
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on 2011-002754-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002754-31.